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Inflammation Does Not Always Kill Hepatocytes During Liver Damage
To the Editor:
We read the article by Horiguchi et al.1 with great interest. It is a
commonly accepted dogma that inflammation induces necrosis and
apoptosis of hepatocytes during liver damage. However, clinicians
have found that inflammation does not always correlate with hepato-
cellular damage in chronic liver disease. How to explain the conflict?
By using a well-established model of mice with specific deletion of
signal transducer and activator of transcription 3 in myeloid cells
(STAT3mye/), Horiguchi and colleagues surprisingly found more
inflammatory cells, eg, neutrophils, but less necrosis/apoptosis in the
liver of STAT3mye/ mice than in wild-type mice after carbon tetra-
chloride (CCl4) treatment. STAT3
mye/ mice had higher hepatic
STAT3 activation and became resistant to hepatic oxidative stress af-
ter CCl4 injection compared with wild-type mice. In contrast to
STAT3mye/ mice, hepatocyte-specific STAT3 knockout
(STAT3Hep/) mice had more liver necrosis/apoptosis but less
inflammation after CCl4 treatment compared with wild-type mice. An
additional deletion of hepatocyte STAT3 in STAT3mye/ mice
restored CCl4-induced hepatic necrosis but reduced liver inflamma-
tion. This study suggests that inflammation associated with a predomi-
nance of hepatoprotective cytokines may reduce rather than accelerate
hepatocellular damage via activation of hepatocyte STAT3 in CCl4-
induced liver damage. The data elucidate a potential mechanism that
inflammation does not always correlate with hepatocellular damage.
Interestingly, the same group had also previously investigated
inflammation and hepatocellular damage in the same strain of
STAT3mye/ mice treated with concanavalin A (ConA) or etha-
nol.2,3 STAT3mye/ mice had higher inflammation concomitant
with more severe hepatocellular damage compared with wild-type
mice after ConA or ethanol treatment. The discrepancy between
ConA- and CCl4-induced liver damage in STAT3
mye/ mice
could be attributable to the different T helper type 1 (Th1) cyto-
kine (IFN-c) responses in these two models. In STAT3mye/
mice, ConA treatment elevated serum IFN-c levels to more than
2500 pg/mL, whereas CCl4 treatment only elevated IFN-c levels to
15 pg/mL. Such high levels of IFN-c in the ConA model not only
directly induce liver damage but also inhibit the hepatoprotective
STAT3 signal in the liver, further promoting liver injury.3 In addi-
tion, ethanol consumption significantly inhibited STAT3 activation
in STAT3mye/ mice. Thus, the protective role of STAT3 is inhib-
ited in both models of ConA and ethanol treatment. These data sug-
gest that the etiology of liver disease plays a critical role in determin-
ing the interplay between inflammation and hepatocellular damage.
In general, the ratio between proinflammatory and anti-inflamma-
tory factors controls the inflammatory level during liver damage; how-
ever, the fate of hepatocytes is determined by the balance between the
survival and detrimental factors present within the damaged liver. For
example, compared to wild-type mice, STAT3mye/ mice had increased
pro-inflammatory cytokines, eg, IL-6, IL-1, IFN-c, and chemokines in
both the liver and serum.1 However, proinflammatory factors do not
always kill hepatocytes and some of them such as IL-6 protect rather
than kill hepatocytes via activation of survival signal STAT3 in hepato-
cytes. Thus, inflammation is not always a direct killer of hepatocytes.
Besides the dogma that inflammation leads to hepatocyte death,
inflammation is also thought as the critical driver for liver fibro-
genesis. However, many studies have demonstrated that inflamma-
tion does not always correlate with liver fibrosis in patients with
chronic liver disease.4 On the other hand, it is well recognized that
degradation of fibrosis needs inflammation.5 Thus, whether inflam-
mation is a friend or a foe is not a simple question.
Here, we have three questions for the authors: First, in patients
with acute liver failure, inflammatory cells, especially monocytes
and macrophages, are central to systemic inflammatory response
syndrome (SIRS), multiple organ dysfunction syndrome (MODS),
and compensation anti-inflammatory response syndrome (CARS).6
Compared with SIRS patients, patients with MODS have similar
levels of proinflammatory cytokines, but higher levels of anti-
inflammatory cytokines that suppressed the functions of peripheral
and hepatic inflammatory cells. Similarly, in STAT3mye/ mice,
CCl4 treatment resulted in early elevation of proinflammatory
cytokines (at 12 hours after treatment), which remained at the
same levels or was decreased at later time points (24 hours). In
contrast, the levels of the anti-inflammatory cytokine IL-10 were
higher at later time (24 hours) than earlier time (12 hours) points.
The situation looks very similar to the early stage of MODS in
patients with acute liver failure. It would be very interesting to further
investigate the ratio of proinflammatory and anti-inflammatory cyto-
kines/chemokines in STAT3mye/ mice at 36 hours after CCl4 treat-
ment. Second, the authors investigated the relationship between
inflammation and hepatocellular damage in ‘‘chronic’’ liver disease.
However, the maximal CCl4 treatment time period in the present
study was 72 hours, and most of data were obtained from the mice
treated with CCl4 within 24 hours. It would be very interesting to
investigate the inflammation and hepatocelluar damage in real
‘‘chronic liver disease’’, eg, mice subjected to 4 weeks of CCl4-treat-
ment. Finally, we are very interested in the relationship between
inflammation and fibrosis in these mice treated chronically with CCl4.
Anyway, we appreciate Horiguchi and colleagues for providing
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Reply:
We highly appreciate the comments by Weng and colleagues.
Our laboratory has been focusing on the role of inflammation in
liver injury, fibrosis, and regeneration by using a model of myeloid
cell–specific signal transducer and activator of transcription 3
(STAT3) knockout (STAT3mye/) mice. As it was previously
reported, STAT3mye/ mice are highly susceptible to endotoxin
shock with increased production of inflammatory cytokines.1 We
demonstrated that STAT3mye/ mice were resistant to liver dam-
age after carbon tetrachloride (CCl4) injection,
2 but more suscepti-
ble to concanavalin A–induced and ethanol-induced liver damage,
accompanied by more inflammatory cells in the liver.3,4 We
believe, as Weng and colleagues summarized, the balance between
pro- and anti-inflammatory cytokines determines the fate of hepa-
tocyte survival or death. These results suggest that the etiology of
liver injury determines whether inflammatory cells contribute to
attenuating or worsening liver damage.
Weng et al. also raised an important point regarding the
effect of inflammation on liver fibrogenesis. Although we have
not examined CCl4-induced chronic liver injury and fibrosis in
STAT3mye/ mice, the effects of inflammation on fibrogenesis
in these mice may be complex. Inflammation not only contri-
butes to fibrogenesis, but also plays an important role in the
resolution of liver fibrosis.5 In our study, STAT3mye/ mice
had high levels of liver inflammation associated with higher lev-
els of tumor necrosis factor-a, interleukin-1 (IL-1), and IL-6,
which are known to promote liver fibrosis, but also higher levels
of IL-10 and interferon-c, which are known to inhibit liver
fibrosis. The balance between these pro- and antifibrogenic cyto-
kines will likely play an important role in determining the pro-
gression of liver fibrogenesis in STAT3mye/ mice after chronic
CCl4 treatment.
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Screening for Biliary Atresia: Swiss Stool Color Card
To the Editor:
With great interest, we read the report by Lien et al.1 on their ex-
perience with using a stool color card (SCC) for the early identifica-
tion of babies with biliary atresia. So far, Taiwan is the only country
with regular, nationwide screening for this devastating disease. With
this screening, the age for Kasai hepatoportoenterostomy has signifi-
cantly dropped, and this has meant a significant increase in jaundice-
free survival with the native liver at the age of 3 years. The same Tai-
wanese group has shown that the sensitivity and specificity of the SCC
for the detection of biliary atresia are 97.1% and 99.9%, respectively.2
Biliary atresia is one of the most progressive fibrogenic liver dis-
eases. The more advanced the liver fibrosis is at the time of the
Kasai operation, the worse the chances are for the child to live
with his or her own liver; increased age at the time of surgery has
a progressive and sustained deleterious effect on the results of the
Kasai operation until adolescence.3-5
The criteria for a condition to be considered appropriate for
newborn screening are as follows: (1) the condition is an important
health problem; (2) there is a recognizable latent period or an early
symptomatic period during which intervention may be beneficial; (3)
there are suitable screening tests or examinations that are acceptable, reli-
able, easy to apply, and available; and (4) there are accepted treatments
that are available and beneficial when they are applied early.6,7 The
implementation of screening for biliary atresia is thus justified. Moreover,
the reported results convincingly demonstrate that in Taiwan, the SCC is
a simple, noninvasive, efficient, low-cost, and applicable mass screening
method for the early diagnosis and management of biliary atresia.
These considerations led to the design of a Swiss national biliary
atresia screening pilot program, which was started in 2009. The
Swiss SCC is available in German, French, Italian, and English (Fig.
1). It is explained and handed out to the parents after their child’s
birth by the attending pediatrician or midwife. An instructive Web
site for parents and health care personal has been established (http://
www.basca.ch). The SCC and the baby’s stool color are checked dur-
ing the first visit with the treating physician, usually at the age of 4
weeks. During the current pilot period for the screening, SCC data
are immediately transmitted to the coordination center in Geneva,
Switzerland, to evaluate the feasibility and acceptance of the screen-
ing program: Switzerland obviously has a culture and mentality dif-
ferent from those of Taiwan. If an abnormal stool color is discov-
ered, a further evaluation of the baby is immediately performed. By
signing the SCC, the parents give their informed, written consent to
the physician to communicate the data to the coordination center.
The current program is open to all interested physicians, and
SCCs can be ordered for free via the Web site (http://www.basca.
ch). The screening is voluntary, and money is not received by the
patient, the participating physician, or the coordination center.
BARBARA E. WILDHABER, M.D.
Service of Pediatric Surgery
Children’s Hospital of Geneva
University Hospital of Geneva
Geneva, Switzerland
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Fig. 1. English version of the
Swiss SCC for biliary atresia screen-
ing. Published with the permission of
the program director.
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Reply:
We appreciate the comments from Dr. Wildhaber. Biliary
atresia (BA) is the most common cause of liver death in children.
Through the stool color card screening program, the prognosis of
BA can be improved remarkably by early detection and timely
surgery. The stool color card screening program is indeed a non-
invasive, low-cost, and simple screening tool that is suitable for
mass screening.1,2 We are pleased to learn of the launch of the
Swiss national biliary atresia screening program. This is a positive
support to our stool card screening program in Taiwan. We hope
to see more countries begin the implementation of the universal
stool color card screening program for BA in children. As we
understand, experts from quite a number of countries, including
Canada, Malaysia, Australia, and the Philippines, among others,
have started or are planning a pilot study for the stool color card
screening program for BA.
Our stool color card is available in other languages for new
immigrants to Taiwan, including versions in English, Vietnamese,
Thai, Indonesian, and Khmer (Kampuchea). In addition, the stool
color card has been integrated into a child health booklet. Educa-
tional lectures were given to health and medical personnel, and
periodically to day care workers.. Posters were also put up in local
clinics and hospitals to propagate the related knowledge. Many
previous studies had shown the importance of earlier detection for
BA.3–5 Our experience provides evidence that the stool color card
is a good screening tool for BA. Continuous efforts to actively
promote early detection is mandatory to improve the long-term
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Misuse of Scoring Systems
To the Editor:
We wish to comment on the article entitled ‘‘Pathologic Crite-
ria for Nonalcoholic Steatohepatitis: Interprotocol Agreement and
Ability to Predict Liver-Related Mortality’’ by Younossi et al.,1
which was recently published in HEPATOLOGY. The stated goals of
the study were 2-fold: (1) to compare the results of biopsy inter-
pretations made according to three previously published histologi-
cal scoring systems2-4 and a previously unpublished system1 for the
histopathological diagnosis of nonalcoholic steatohepatitis (NASH)
and (2) to compare the use of these systems for the prediction of
long-term mortality. The study cohort consisted of patients with
biopsy-proven nonalcoholic fatty liver disease (NAFLD) who had
at least 5 years of follow-up.
Details of the utilization of the previously described histological
scoring systems provide insight into our concerns. Matteoni et al.2
described a system for the categorization of the spectrum of dis-
eases in NAFLD and classified cases into four types: (1) steatosis,
(2) steatosis plus inflammation, (3) steatosis plus ballooning, and
(4) steatosis plus Mallory-Denk bodies or fibrosis. This classification
system was not used to identify the presence or absence of NASH in
the original study according to Younossi et al. The degree of inflam-
mation and its location (portal or lobular) were not specified in the
system, nor was the degree of fibrosis or its zonality (perisinusoidal
or portal). On the other hand, the Brunt proposal3 for grading and
staging NASH was just that: a proposal, published in the same year
as the Matteoni classification system, that followed the same para-
digm used in chronic hepatitis for separating grading (activity) and
staging (fibrosis). This proposal was, however, not intended for estab-
lishing a diagnosis of NASH. This system was applied to liver biopsy
samples only after NASH had been diagnosed and not to cases with
steatosis only or steatosis and inflammation. Thus, the use of ‘‘fat
plus lobular inflammation’’ for a ‘‘Brunt’’ diagnosis of ‘‘NASH’’ by
Younossi et al. is the result of a misunderstanding, and this misappli-
cation of the proposal has led to their conclusion that the system
results in the overdiagnosis of NASH.
The National Institutes of Health–sponsored NASH Clinical
Research Network system, which is called the Kleiner scoring
system,4 also separates the activity [nonalcoholic fatty liver dis-
ease activity score (NAS)] and the stage (fibrosis). The NAS
comprises steatosis, inflammation and ballooning only, and no
fibrosis, as implied by Younossi et al.1 Importantly, the NAS
scoring system was not intended to be used as a surrogate for a
diagnostic determination of NASH versus NAFLD without
NASH. Although, as noted by Younossi et al., other authors
have used the NAS as a surrogate for establishing a diagnosis of
NASH, neither the NASH Clinical Research Network nor we as
the participating pathologists have ever supported the use of the
system for diagnosis in writing or presentations. Furthermore, as
we have recently demonstrated, although higher NAS scores cor-
relate with a diagnosis of NASH statistically, they have separate
and distinct clinical meanings, and the NAS cannot replace the
histological diagnosis.5
Unfortunately, Younossi et al.1 also assessed both the Brunt and
Kleiner scoring systems for another purpose for which they were
not designed: the prediction of liver-related mortality. Interestingly,
they tested these systems against the Matteoni system, which was
developed specifically for this purpose. Several statistical analyses
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were performed and led to a final conclusion confirming what
has been shown in many studies of NASH over the past decades:
hepatic fibrosis is a predictor of long-term morbidity/mortality.
In conclusion, the comparison of histological grading and stag-
ing systems and the validation of their elements against clinical
outcomes are important goals in clinical investigation. Of utmost
importance in these types of studies, however, is careful attention
to the details of the methods that are used. The ‘‘Brunt’’ and
‘‘NAS’’ systems, as applied in this article,1 have not been appropri-
ately used in this context, and we emphasize this to the editor and
the readers of this article to dispel any potential misunderstandings
about the usefulness of these grading systems when they are
applied in the appropriate way.
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Reply:
We thank Dr. Brunt and colleagues for their interest in our ar-
ticle. We agree that validation against clinical outcome is important
for any grading and staging system. Our study was designed to
examine the relationship of histopathologic features to liver-related
mortality in nonalcoholic fatty liver disease (NAFLD), and so
among other assessments, we included two widely used scoring
systems.1,2
Regarding NAFLD activity score (NAS), we agree that the orig-
inal description and subsequent confirmation discouraged its use
for diagnosis of nonalcoholic steatohepatitis (NASH),2,3 and as
noted in our article, our results confirmed this.
Regarding the score presented by Brunt et al., we strictly
adhered to the definitions in its original description.1 It is true that
the score was intended for grading biopsies diagnosed with NASH.
However, the article’s description of mild NASH is quite clear and
precise: ‘‘Steatosis (predominantly macrovesicular) involving up to
66% of biopsy; may see occasional ballooned zone 3 hepatocytes;
scattered rare intra-acinar polymorphonucleocytes and/or intra-aci-
nar lymphocytes; no or mild portal chronic inflammation.’’ Steato-
sis and mild lobular inflammation are mandatory parts of this defi-
nition of mild NASH, but ballooning is optional. Elsewhere, the
description of mild NASH includes ‘‘Ballooning and disarray are
minimally present, if at all.’’ It also noted ‘‘these biopsies meet the
minimum criteria for steatohepatitis.’’ By contrast, the description
of moderate NASH says ‘‘Ballooning and disarray are always pres-
ent.’’ Therefore, this means that any biopsy with steatosis and mild
lobular inflammation can be interpreted as mild NASH according
to the original criteria described in Brunt et al.
It is important to remember that regardless of intended use, all
pathologic grading and staging systems are based on the premise
that what looks bad to the pathologist will be worse for patients. If
the goal of a clinical trial is to improve histologic characteristics, it
is with the presumption that histologic improvement will decrease
an adverse long-term outcome. A true evidence-based test of that
hypothesis requires a study with long-term outcome as the end-
point. If under the rubric of NASH we exclude Brunt’s grade 1 or
mild NASH, its performance in predicting liver-related mortality
improves significantly. In contrast, NAS does not directly translate
to a diagnosis of NASH and is more useful for assessing short-
term histologic changes in clinical trials, as was its intent.
Finally, we must disagree with the statement that ‘‘many’’ studies
have shown that hepatic fibrosis is a predictor of long-term morbid-
ity and/or mortality in NASH. We know of only three other nonal-
coholic fatty liver disease studies (combined patients ¼ 302) that
assessed histology and long-term outcome. It seems likely that fur-
ther advances in histologic predictors of natural history will require a
much larger number of patients with long-term follow-up.
ZACHARY GOODMAN, M.D., PH.D.1
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Efforts at Making the Diagnosis of Acute-Onset Autoimmune Hepatitis
To the Editor:
We read with great interest the article by Stravitz et al.,1 who
report that patients with indeterminate acute liver failure (ALF) of-
ten have features of autoimmune hepatitis (AIH) according to his-
tological, serological, and clinical analyses. Fifty-eight percent of
their patients with indeterminate ALF were diagnosed with proba-
ble AIH-ALF on the basis of pathological features, and they had
higher serum globulin levels and higher levels of anti-nuclear antibod-
ies, anti–smooth muscle antibodies, or both in comparison with
patients without histological findings suggestive of probable AIH-ALF.
As hepatologists struggling against intractable liver diseases in
Japan, we applaud their efforts at making the diagnosis of acute-
onset AIH.
In past Japanese surveys of ALF, a specific etiology could not be
identified in 30% to 40% of adult patients.2 Since the establish-
ment of the criteria of the International Autoimmune Hepatitis
Group3 and the recognition of acute-onset AIH, patients with
autoimmune ALF have begun to be diagnosed.4 However, in the
early stages of their illness, they often demonstrate a histological
pattern atypical for AIH that consists of centrilobular necrosis with
or without portal changes.5-7
Recently, we have also reported that AIH is not a rare cause of
ALF in our unit, and the number of patients with unknown causes
could decrease according to the precise diagnosis of AIH, which is
based on a combination of the aforementioned pathological fea-
tures and the original revised criteria.8 In our unit, AIH has been
involved in 29% of ALF cases, and unknown causes have been
involved in 12%; this means that in comparison with the results of
a national survey, approximately half of our patients with unknown
causes have been diagnosed with AIH-ALF.
In our recent studies,7-10 the severity of acute-onset AIH was
not high at its onset in most patients, but some of them advanced
to severe diseases without a precise diagnosis or treatment. For an
early diagnosis, it is most important to exclude other causes
systematically, to remember acute-onset AIH in the differential
diagnosis, and then to apply the scoring system; comprehensive
evaluations of clinical, biochemical, radiological, and histological
features are necessary. In particular, a precise pathological evalua-
tion plays an important role in the differential diagnosis, as the
authors describe. However, this is complicated by the fact that
there is still no gold standard for making the diagnosis of acute-
onset AIH, as the authors repeatedly note.
We believe that one of the pathological characteristics of acute-
onset AIH is its histological heterogeneity, especially in severe and
fulminant AIH. Histological heterogeneity leads to radiological het-
erogeneity. Unenhanced computed tomography often shows hypo-
attenuated and hyperattenuated areas, with the former reflecting
massive hepatic necrosis and the latter reflecting regenerative
islands. Ultrasound shows similar heterogeneity. Histological heter-
ogeneity also leads to clinical heterogeneity. The time from onset
to admission to our unit did not differ with the clinical severity
(nonsevere, severe, or fulminant), and the time from onset to histo-
logical examination did not differ with the histological features
(chronic hepatitis, severe acute hepatitis, or massive/submassive
necrosis; Fig. 1).
Fig. 1. Associations between
(A) the clinical severity and the
time from onset to admission and
(B) the histological features and
the time from onset to histologi-
cal examination.
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Characteristic morphological patterns of liver necrosis and
regeneration should exist in patients with acute-onset AIH, and a
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Autoimmune Acute Liver Failure
To the Editor:
We read with great interest the article entitled ‘‘Autoimmune
Acute Liver Failure: Proposed Clinical and Histological Criteria’’
by Stravitz et al.1
Our reading of this article has given rise to several comments. It is
necessary to be very cautious when one is ranking histological features
first in the diagnosis and management of severe forms of autoimmune
disease; during their study, Stravitz et al.1 examined liver biopsy sam-
ples from 72 of 204 patients (i.e., 35% of the total cohort). However,
the use of different liver biopsy techniques, such as transjugular liver
biopsy, native liver biopsy, and postmortem biopsy, may have induced
variations in the histological patterns. Centrilobular necrosis (CN),
which corresponds to massive hepatic necrosis type 1 in this study, is
an important but infrequent histopathological pattern of autoimmune
hepatitis; centrilobular necrosis with sparing of the portal tracts was
present in 3.5% of the cases reported by Hofer et al.2 This particular
pattern is of crucial importance because it may be indicative of an
early stage of the disease. For the series described by Stravitz et al., it
would be interesting to have a description of the phenotype and,
more specifically, the prognosis of the patients with isolated centrilob-
ular necrosis. The fact that the centrilobular zone is damaged during
an early stage by the immune process is intriguing and suggests that
specific autoantigens in this area could be presented to the immune
system early during the course of liver disease. Clearly, the identifi-
cation of these potential targets during an initial phase of the
disease would be of considerable interest. In addition, it is unfor-
tunate that the identification of a pattern typical of severe auto-
immune hepatitis (AIH) is based only on this experience; in sev-
eral reports, researchers have attempted to describe this entity, and
experiences besides those of the US Acute Liver Failure Study
Group should be cited.3-6 In particular, the characteristics of the
patients may differ between the studies. In our cohort, 8 of 16
patients (50%) suffered from grade 3/4 encephalopathy,3 whereas
26 of 72 patients (39%) in Stravitz et al.’s study did.
The most important and problematic issue in the management
of severe autoimmune liver disease is corticosteroid therapy. Of
course, if a response to corticosteroid therapy is an important argu-
ment in favor of an autoimmune process, it is important that any
decision to administer this therapy be balanced against the high
potential risk of sepsis; infections occurred in 5 of 12 patients
(42%) during steroid therapy in our study.3 If treatment failure
seems to be predicted by changes in the Model for End-Stage Liver
Disease–Sodium score and the UK Model for End-Stage Liver Dis-
ease score on day 7,7 specific scores on entry must be defined for
making decisions about the administration of steroid therapy.
JEAN-CHARLES DUCLOS-VALLÉE, M.D., PH.D.1,2,3
PHILIPPE ICHAI, M.D.1,2,3
DIDIER SAMUEL, M.D., PH.D.1,2,3
1Centre Hépato-Biliaire
Hôpital Paul Brousse
Assistance Publique–Hôpitaux de Paris
Villejuif, France
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Reply:
We appreciate the comments of Drs. Fujiwara and Duclos-
Vallée regarding our article, ‘‘Autoimmune acute liver failure: pro-
posed clinical and histological criteria.’’1 Dr. Fujiwara reports that
approximately 50% of their patient population with acute liver
failure (ALF) of unclear etiology was ultimately diagnosed with
autoimmune ALF (AI-ALF) on the basis of liver histology and
clinical parameters, similar to findings in our series (58%). The
investigators advise caution in interpreting our work regarding the
heterogeneity of histological findings in liver specimens from
patients with ALF. Dr. Fujiwara presents data that demonstrate no
difference between the time of onset of hepatitis to time of admis-
sion or liver biopsy between patients with autoimmune hepatitis
presenting as acute-onset hepatitis, chronic hepatitis, or ALF, with
a large degree of overlap, supporting the clinical heterogeneity of
the disease.
Dr. Duclos-Vallée also raises concern about the fact that two-
thirds of our liver specimens were sections from explants, whereas
the remainder were transjugular needle biopsies. The lack of uni-
form biopsy technique, they suggest, may have influenced our
results by increasing the probability of finding specific features of
autoimmunity in the larger specimens obtained from an explant.
We did not, however, find statistically significant differences in the
prevalence of the four features of autoimmunity between specimens
obtained from explanted livers and those obtained by transjugular
biopsy.
Dr. Duclos-Vallée also requested further correlation between
patients with centrilobular necrosis and their clinical phenotype
and outcomes. Patients with central perivenulitis were characterized
by a longer jaundice-to-encephalopathy interval, and a poorer
prognosis (higher incidence of liver transplantation). These attrib-
utes can be ascribed to a more subacute liver injury in patients
with AI-ALF compared to those with other indeterminate etiolo-
gies. Perhaps due to small numbers (13 of 72 patients; 18%), those
patients with exclusive centrilobular necrosis were not clinically dif-
ferent than those without this feature.
Finally, Dr. Duclos-Vallée and colleagues raise concern about
administering corticosteroids to patients with suspected AI-ALF, a
major rationale for performing our study. We strongly agree with
their contention that corticosteroid administration may introduce a
significant risk of infection, and that no convincing evidence of ef-
ficacy exists.2 It should be noted, however, that no randomized,
placebo-controlled studies have explored the efficacy of corticoste-
roids in patients with rigorously defined AI-ALF. In the absence of
such information, we would reserve the administration of cortico-
steroids to patients with recent-onset AI-ALF and low-grade he-
patic encephalopathy. Certainly, corticosteroids are unlikely to
improve the transplant-free survival of a patient with AI-ALF late
in the clinical course of the syndrome or with clinical attributes of
poor outcome.
R. TODD STRAVITZ, M.D.1
JAY H. LEFKOWITCH, M.D.2
1Section of Hepatology, Virginia Commonwealth University
Richmond, VA
2Department of Pathology, Columbia University, New York, NY
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Occult Hepatitis B Virus Infection and Hepatocellular Carcinoma Development in Patients
with Chronic Hepatitis C
To the Editor:
We read with interest the article by Lok et al. that assessed
occult hepatitis B virus (HBV) infection in patients who are nega-
tive for hepatitis B surface antigen and who have advanced chronic
hepatitis, from the Hepatitis Antiviral Long-Term Treatment
against Cirrhosis (HALT-C) trial, who did or did not develop he-
patocellular carcinoma (HCC).1 They conclude by affirming that
occult HBV infection has no role in HCC development in U.S.
patients with chronic hepatitis C.
After a detailed evaluation, we have several concerns regarding
this conclusion. The authors themselves admit that their study has at
least four main limitations. First, a limited number of patients with
HCC were evaluated, and the diagnosis of cancer was simply pre-
sumed in some cases. In the HALT-C trial, the patients were ran-
domly assigned to maintenance pegylated interferon or to no further
treatment, and it would be relevant to know how the occult-positive
patients were distributed according to treatment received and to defi-
nite or presumed HCC diagnosis. The second and third stated limi-
tations concern the long storage duration and the very limited size of
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biopsy specimens examined: 2-3 mm of tissue obtained by percuta-
neous needle biopsy cannot provide reliable results. Theoretically,
such a small piece of tissue may not actually be liver or could be
fibrotic tissue. The fourth stated limitation concerns the lower num-
ber of HBV genomic regions tested as compared to previous studies
that provided different results. It is also highly surprising that the X
genomic region (the viral gene mainly involved in the direct onco-
genic role of HBV) was not searched in a study evaluating the associ-
ation between HBV persistence and HCC development. Moreover,
there is generic information about patient origins and, consequently,
about the presumable infecting genotypes. Thus, the possibility that
sensitivity and specificity of both amplification primers and probes
was inadequate in a number of cases cannot be ruled out.
This study confirms previously reported (and not denied) data con-
cerning the association between occult HBVand severe chronic hepatitis
C in the United States.2 Considering the very low prevalence of HBV
infection in the United States, this observation is interesting,3 and it
would be very important to know the prevalence of occult HBV in U.S.
patients infected with hepatitis C virus, with minimal liver damage.
Altogether, we feel that there is still ample room for a role of
occult HBV infection in the development of HCC in patients with
chronic hepatitis, and that its categorical exclusion in the U.S.
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Reply:
We appreciate the interest of Dr. Raimondo and colleagues in
our article.1 Of the 91 patients with hepatocellular carcinoma
(HCC) who were tested for hepatitis B core antibody (anti-HBc) in
serum, 39 of 53 (74%) patients negative for anti-HBc and 32 of 38
(84%) patients positive for anti-HBc met criteria for definite HCC.
Among the 28 patients with HCC who were tested for hepatitis B vi-
rus (HBV) DNA in the liver, 18 of 25 (72%) HBV DNA–negative
and two of three (67%) HBV DNA–positive patients met criteria for
definite HCC. We would like to point out that the diagnostic criteria
for presumed HCC in the HALT-C Trial protocol—a new mass on
ultrasound in conjunction with two other imaging studies showing a
lesion with arterial enhancement, with or without washout or evi-
dence of progression on follow-up—are very stringent and most, if
not all, patients with presumed HCC would have met the current
guidelines for diagnosis of HCC. Of the 25 patients with HCC who
had undetectable HBV DNA in the liver, 10 were randomized to
maintenance peginterferon and 14 to no treatment, whereas one
developed HCC during the lead-in phase and was not randomized.
All three patients with HCC who had detectable HBV DNA in the
liver were in the control group. We acknowledge the limitations of
the data based on testing of HBV DNA in the liver; however, sero-
logical data showed clearly that despite evidence of a high prevalence
of prior HBV infection, there was absolutely no association with
HCC. We note that failure to find an association of prior or occult
HBV infection and HCC among patients with HCV-related cirrho-
sis is not confined to the United States. Even in Italy, one large study
found no association between anti-HBc in serum and HCC or liver-
related deaths.2
ANNA S. LOK, M.D.1
JAMES E. EVERHART, M.D.2
1Division of Gastroenterology, University of Michigan Medical Center
Ann Arbor, MI
2National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Bethesda, MD
References
1. Lok AS, Everhart JE, Di BisceglieAM, Kim HY, Hussain M, Morgan
TR; the HALT-C Trial Group. Occult and previous hepatitis B virus
infection are not associated with hepatocellular carcinoma in US
patients with chronic hepatitis C. HEPATOLOGY 2011; doi: 10.1002/
hep.24257.
2. Stroffolini R, Almasio P, Persico M, Bollani S, Benvegnù L, Di Cos-
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Association Between Human Leukocyte Antigen DP Gene Polymorphisms and
Chronic Hepatitis B in a Chinese Population
To the Editor:
We read with great interest the article by Guo et al.,1 which
suggested that 11 polymorphisms of human leukocyte antigen DP
genes were significantly associated with chronic hepatitis B in a
Chinese population. These significant associations were first
reported by a genome-wide association study in Japanese and Thai
populations.2 Since then, besides the study by Guo et al, 1 two
studies further confirmed the significant associations.3,4 These stud-
ies are very important, because the findings would help us more
deeply understand the genetic mechanism of chronic hepatitis B.
However, after carefully inspecting the article by Guo et al.,1 we
noted four issues that should be considered.
First, the authors stated that the Bonferroni correction was the
current P value times 4. In my opinion, it is not true. On the basis
of data in Table 2, the P value should be multiplied by 8 [(2 hap-
lotype blocks þ 2 variants (rs3135021þrs11752643))  2 group
comparisons]; in Table 3, the multiplication should be by 12 [((2
haplotype blocks þ 1 variant (rs3135021))  2 genotype compari-
sons for each variant  2 group comparisons)]. Therefore, the
P value for statistical significance in Table 2 should be 0.05/8 ¼
0.00625 and that in Table 3 should be 0.05/12 ¼ 0.00417. On
the basis of the new P values, the association between rs2395309
and chronic hepatitis B is not statistically significant after Bonfer-
roni correction (Table 3).
Second, the authors did not provide the statistical powers of
their studied sample for each variant. Therefore, I am not certain
whether the statistically significant results are the true ones or are
due to chance. It is always better to present the statistical powers.
Third, it is more proper to move the notes of Armitage’s trend test
in Table 2 to the notes in Table 3, because the three genotypes for each
variant in Table 3, rather than those in Table 2, showed the trends.
Fourth, the order in which the three genotypes are listed under
each SNP variant, namely rs9277341, rs9277535, rs3117222, and
rs9380343, is not uniform in Table 2 and Table 3, and this would
confuse the readers. Therefore, we suggest that the authors should
keep odds ratios with 95% confidence intervals in the same direc-
tion in order to present their results more clearly.
CHIBO LIU, M.B.
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Reply:
We do appreciate that there are legitimate differences of opin-
ion with respect to correction for multiple tests as the letter by
Dr. Liu aptly illustrates. Our study1 was designed to replicate a
previously published genome-wide association study.2 One opin-
ion is, in this case, that a correction for multiple comparisons is
unnecessary. In our study, however, we still address it. We state
that a Bonferroni test may be too conservative given the noninde-
pendence of adjacent single-nucleotide polymorphisms (SNPs)
strongly associated by linkage disequilibrium3 (see Johnson et al.3
for our detailed discussion of linkage disequilibrium statistics on
genome-wide association studies). Nonetheless, even if we con-
cede to the more stringent statistical correction offered by Dr.
Liu in his comment (0.05/8 ¼ 0.00625 for table 2 and 0.05/12
¼ 0.00417 for table 3), nearly all the associations for SNP al-
leles (table 2) or genotypes (table 3) still achieve statistical sig-
nificance after correction. Only rs3135021 fails significance. We
feel that our data are robust and statistically strong in support
of the associations of the SNP alleles, genotypes, and haplotypes
illustrated in table 2 to table 4 and figure 1.
The statistical power of our study for the additive model is 89%-
100%, based on case number, control number, disease prevalence
(0.08), significance level (0.05), disease allele frequency (0.334–
0.797), and genotype relative risk (1.5). Also, the data reported in
table 2 were actually from Armitage’s trend test (computed with
SAS Genetics software), which is most useful when there is an addi-
tive allele effect on the disease susceptibility.
As for the direction (i.e., the polarity of odds ratios [ORs]), this
format is also a matter of taste. We chose to base our tables on the risk
allele (protective allele as a reference) with OR < 1.0, which we state.
For example, for rs2395309, the OR should be
1/0.71 ¼ 1.41, and 95% confidence interval should be 1.16–1.69
(formula is 1/0.86 ¼ 1.16, 1/0.59 ¼ 1.69) for risk allele G. We realize
that use of the term ‘‘risk allele’’ might be confusing, because some al-
leles protect whereas others are susceptible, as indicated by the OR.
For this confusion, we stand corrected. We apologize for the confu-
sion, but when one examines the OR, it seemed clearly stated to us.
For table 3, we list the reference group (OR ¼ 1.0), and the
most common genotype was used as a reference for each SNP.
XIUCHAN GUO, M.D.1
RANDALL C. JOHNSON, MHS2
STEPHEN J. O’BRIEN, PH.D.2
1State Key Laboratory for Infectious Diseases Prevention and Control
Institute for Viral Disease Control and Prevention
Chinese Center for Disease Control and Prevention
Beijing, China
2Laboratory of Genomic Diversity
National Cancer Institute–Frederick
Frederick, MD
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Neutralization of Lipopolysaccharide Effects in
Liver Diseases, the Quest for the Holy Grail
To the Editor:
We read with great interest the article in HEPATOLOGY by Nolan
on the role of lipopolysaccharide (LPS) in liver injury.1 This review,
written by a pioneer of this approach, details the main studies that
progressively established gut-derived LPS as a key cofactor in acute
and chronic liver disease in the last half-century and more recent
studies that tried to prevent LPS-induced damages by reducing or by
neutralizing plasma LPS or proinflammatory cytokines. However, we
think some important recent studies should have been discussed in
this review.
Among the studies exploring possibilities to neutralize LPS,
those which assessed the effects high-density lipoprotein (HDL)
have not been mentioned.2-4 HDL particles are multifunctional
lipoprotein complexes that transport lipids and have several
anti-inflammatory properties. In cirrhosis, HDL plasma concen-
trations are decreased and could impair the host’s ability to
neutralize LPS.3 In cirrhotic rats with ascites, two recent studies
have shown that HDL administration reduced the effects of
LPS on tumor necrosis factor-a production2,4 and systemic
hemodynamics, restoring liver endothelial nitric oxide synthase
activity and decreasing portal pressure.2 These studies suggest
that the excessive proinflammatory response to LPS in cirrhosis
may be attributable, at least in part, to reduced LPS neutraliza-
tion by HDL. Incubation of whole blood with reconstituted
HDL prevents LPS-induced tumor necrosis factor-a and inter-
leukin-6 overproduction by monocytes of patients with cirrho-
sis.3 Therefore, we believe that restoring HDL content in
patients with cirrhosis may be a research avenue to follow in
the future.
We are conscious that mentioning all the studies related
to this crucial subject is very difficult, but we think that the
studies we report here are worth being cited in such a
review.
ARNAUD GALBOIS, M.D.1,2,3
DOMINIQUE THABUT, M.D., PH.D.2,3,4
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Alpha-Fetoprotein in Hepatocellular Carcinoma Surveillance: Wake Not the Dead
To the Editor:
We read with interest the letter by Marrero and El-Serag that
calls for the inclusion of alpha-fetoprotein (AFP) in the American
Association for the Study of Liver Diseases (AASLD) updated
guidelines for the management of hepatocellular carcinoma
(HCC).1,2 However, we disagree with their conclusions and feel
that the AASLD recommendation to perform HCC surveillance
with ultrasonography (US) alone is supported by solid evidence.1,2
The evidence supporting surveillance programs for HCC with
liver US with or without AFP testing stems from the results of a
randomized controlled trial and from cohort studies showing that
surveillance improves both detection rate of early HCCs and patient
survival.3-5 However, it is clear that the authors of the AASLD
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guidelines took into account the numerous limitations of AFP testing,
and therefore it is no surprise that they did not include this serological
marker in their HCC surveillance recommendations.2 In fact,
although we may agree with Marrero and El-Serag that the Hepatitis
C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial is
a suboptimal setting to assess the role of AFP for the early detection
of HCC, this study had the precious gifts of providing prospectively
collected data and to include a large population of patients who were
mainly at risk of developing HCC.6 Furthermore, data were available
both at HCC diagnosis and 1 year before, thus being as close as pos-
sible to everyday clinical practice and therefore providing the best evi-
dence currently available.2,6 In this study, the sensitivity of AFP at a
cutoff of 20 ng/mL was low (i.e., 61%) at the time of HCC diagno-
sis, yet at 22% it was unacceptably low 12 months before, when
HCC was likely present in the majority of patients.6 These results are
strikingly similar to those obtained in a case-control study carried out
in a completely different population, where a 20 ng/mL AFP cutoff
showed 60% sensitivity for the diagnosis of HCC,7 although sensitiv-
ity was unacceptably low (i.e., approximately 50%) for single nodules
and/or lesions smaller than 3 cm.8
We feel that the extensors of the updated AASLD guidelines did not
ignore the ‘‘highest level of evidence for the efficacy of US combined
with AFP in research studies’’2 as affirmed by Marrero and El-Serag,1
but evaluated both efficacy and cost-effectiveness. Indeed, the combina-
tion of AFP and US leads to a mere 6%-8% increase in sensitivity for
the detection of early HCC as compared to US alone, with a doubling
in the rate of false-positives and at an unbearable increase (by 84%) in
surveillance-related costs.9,10 Therefore, AFP provides no additional ben-
efit to US, as recently concluded even in the meta-analysis by the Mar-
rero group,10 with a significant worsening of the cost-effectiveness of sur-
veillance.9 To conclude, we feel that the use of AFP as a surveillance test
for HCC should be regarded as a memory, and any effort to increase the
awareness and application of the currently proposed surveillance guide-
lines among physicians in clinical practice should be embraced.
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Treatment Implication from the Potential Association Between Nonalcoholic Fatty Liver
Disease and Cardiovascular Disease
To the Editor:
In recent years, the potential association between nonalcoholic
fatty liver disease (NAFLD) and cardiovascular disease (CVD) has
attracted much interest,1 generating discussion that NAFLD
patients should perhaps be treated not only for their liver disorder
but also owing to their associated cardiovascular risk factors. How-
ever, it seems that at present we cannot draw a definitive conclu-
sion on the association between NAFLD and CVD. I read with
great interest the article by Ghouri et al.,2 who reviewed data from
recent prospective studies and concluded that a diagnosis of
NAFLD is insufficient to consider patients as being at high risk for
CVD. Nevertheless, it is interesting to note that Targher et al.3
recently reviewed the rapidly growing body of clinical evidence
supporting a strong link between NAFLD and the CVD risk.
Therefore, additional effort is encouraged to shed light on the link
between the two disorders.
I do not intend to judge the association between NAFLD and
CVD; however, I sincerely hope the current debatable status will
not hamper the research community to optimize the treatment
strategy. Before drawing a definitive conclusion on the association
between the two disorders, I submit that the NAFLD treatment
strategy, which also possesses the potential to prevent/reduce the
associated risk of CVD, may serve as a good approach for NAFLD
patients. The advantage of this strategy is that if no or only a weak
association between NAFLD and CVD is found, the approach will
not bring additional burden to the patients. There have been
numerous clinical trials of various treatment modalities for
NAFLD as comprehensively reviewed by Lam and Younossi,4
including weight loss agents, insulin-sensitizing agents, lipid-
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lowering agents, antioxidants, probiotics, and other novel com-
pounds. In addition, Satapathy and Sanyal5 recently discussed the
status of current and emerging treatment strategies for nonalcoholic
steatohepatitis patients and highlighted the great potential of anti-
oxidant therapy. Because the treatment strategies for NAFLD and
CVD are similar, it is promising to consider that one of the above-
mentioned treatment modalities for NAFLD could also be applied
for associated risk of CVD.
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Are There More Factors Other than Hepatitis B Virus DNA Level and A1762T/G1764A Mutation in
Liver Tissue that Also Independently Predict Postoperative Survival in Hepatocellular Carcinoma?
To the Editor:
We read with great interest the study by Yeh et al.1 on hepatitis B
virus (HBV)-DNA level and basal core promoter A1762T/G1764A
mutation in liver tissue independently predicting postoperative sur-
vival in hepatocellular carcinoma (HCC). According to the article,
the amount of HBV-DNA in liver tissue and the presence of the ba-
sal core promoter mutation were two independent predictors for
postoperative survival in HCC. The authors also found that a short-
stretch pre-S deletion located between codons 107 and 141 was asso-
ciated with a poorer postoperative prognosis. This study can be
hailed as an original contribution in terms of predicting postopera-
tive survival in HCC; however, we have some concerns about it.
First, as is well known, evidence suggests that HBV genetic
mutations contribute to the risk of HCC. Recent studies have
shown that HBV genotype- or subgenotype-specific mutations,
including C1653T in the EnhII region, T1753V, and the double
mutant A1762T/G1764A in the BCP region, are independent risk
factors for HCC.2 Another study has indicated that pre-S dele-
tions, I68T in surface gene, T1762/A1764, and A1899 are inde-
pendent risk factors for HCC.3 A recent meta-analysis revealed
that the HBV pre-S mutations C1653T, T1753V, and A1762T/
G1764A are associated with an increased risk of HCC. These
mutations alone and in combination may be predictive of hepato-
carcinogenesis.4 We wonder whether the other gene mutations cor-
related with HCC in HBV other than the basal core promoter
A1762T/G1764A mutation (e.g., C1653T, T1753V, A1899) can
independently predict postoperative survival in HCC.
Second, it has not been determined whether hepatitis B e anti-
gen (HBeAg) is associated with postresection survival in HCC.
According to Sun et al.,5 HBeAg was associated with a higher risk
of early recurrence and poorer survival in patients after curative
resection of small HCC. However, Chen et al.3 indicated that
HBeAg positivity is not a negative factor for resection in HCC
patients and has no significant influence on postresection survival.
Therefore, we wonder whether HBeAg was associated with postre-
section survival in HCC in the study by Yeh et al. Given that the
serum samples used in the study had been stored in the serum
bank, we think that the detection of HBeAg in both groups is con-
venient and has great significance.
Finally, a study by Tomimaru et al.6 showed that histological
assessment of the degree of fibrosis in noncancerous tissue is a
unique prognostic factor for primary HCC without hepatitis B or
C viral infection. If this is the case, then is histological assessment
of the degree of fibrosis in noncancerous tissue one of the prognos-
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Risk Factors for Infection in Chronic Hepatitis C: A High Prevalence of Sexual Exposure Among
Human Immunodeficiency Virus–Coinfected Women
To the Editor:
We have read with great interest Tohme and Holmberg’s
review1 in HEPATOLOGY on the sexual transmission of hepatitis C
virus (HCV). They distinguished between heterosexual and homo-
sexual contacts and also between monoinfected and human immu-
nodeficiency virus (HIV)–coinfected patients, and they affirmed
the recently reported increasing incidence of HCV infection among
HIV-positive men who have sex with men.
We analyzed the risk factors for infection in a series of 886 con-
secutive patients [median age ¼ 40 years, interquartile range ¼ 33-
53 years, 521 males (58.8%)] with chronic hepatitis C who were
followed up in our liver unit; 198 of these patients (22.3%) were
HIV-coinfected. A risk-factor questionnaire was prospectively col-
lected by the members of the unit (i.e., us). We considered the risk
factor for HCV infection to be sexual exposure (SEXEXP) only in
patients who fulfilled the following criteria: (1) a negative history
for intravenous drug use (IDU), inhalatory drug use (INHDU), or
blood transfusions (BTs) before 1994 and (b) a sexual partner who
was recognized to be anti-HCV–positive.
The main risk factors in the whole group of patients were IDU
(32.5%), BTs (19.4%), INHDU (8.9%), and SEXEXP (8.6%). In
20.2% of the patients, no risk factors were identified. However, we
found significant differences in the risk factors between males and
females [the main ones were IDU (47.4%) and BTs (30.5%),
respectively; SEXEXP was considered to be the probable risk factor
in only 1.7% of men but in 18.3% of women (P ¼ 0.0000)].
There were also significant differences between monoinfected HCV
patients (n ¼ 687, age ¼ 46 6 14 years) and HIV-coinfected
patients (n ¼ 198, age ¼ 35 6 6 years). In the first group, 24.4%
had a history of BTs, 23.5% had a history of IDU, and 9.1% had
a history of INHDU; in the second group, a history of IDU was
predominant (62.1%), and it was followed by SEXEXP (20.5%).
In our opinion, the more interesting finding is the relationship
between females (n ¼ 365) and SEXEXP as the probable route of
HCV transmission. The definition of SEXEXP was fulfilled by
10% of monoinfected women (n ¼ 292, age ¼ 51 6 15 years),
whereas in the group of HIV-coinfected women (n ¼ 73, age ¼
35 6 7 years), the percentage was more impressive: 49%.
Although this subgroup of coinfected women is small, it seems to
us that this finding is worthy of being reported. The sexual part-
ners of these women are also our patients; most have the same
HCV genotype as their wives, and they usually have a history of
IDU. Thus, we have to rely on clinical histories to exclude this
background in women. In conclusion, we have found SEXEXP to
be a very prevalent risk factor for HCV infection in HIV-coin-
fected women. The transmission of HCV might be secondary to
high viremia levels in their partners in the period before antiretro-
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